Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jan 2010

Dahabreh Issa J, Linardou Helena, Siannis Fotios, Kosmidis Paris, Bafaloukos Dimitrios, Murray Samuel

Abstract excerpt

PURPOSE: The aim of this systematic review and meta-analysis was to characterize common EGFR molecular aberrations as potential predictive biomarkers for response to monotherapy with tyrosine kinase inhibitors (TKI) in non-small cell lung cancer (NSCLC). EXPERIMENTAL DESIGN: We systematically identified articles investigating EGFR status [somatic mutational and gene copy aberrations (copy number)] in patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Gene Dosage

Share to Lung Neoplasms

Share to Prognosis

Share to Protein Kinase Inhibitors

Share to Treatment Outcome

Source

Identifiers

PMID: 20028749
DOI: 10.1158/1078-0432.CCR-09-1660

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer.PMID 20028749Read ↗

Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitorsSemantic proximity Read ↗

Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis.Semantic proximity Read ↗

Clinical Value of EGFR Copy Number Gain Determined by Amplicon-Based Targeted Next Generation Sequencing in Patients with EGFR-Mutated NSCLC.Semantic proximity Read ↗

Genomic characterisation of de novo EGFR copy number gain and its impact on the efficacy of first-line EGFR-tyrosine kinase inhibitors for EGFR mutated non-small cell lung cancer.Semantic proximity Read ↗

Comprehensive characterization and clinical impact of concomitant genomic alterations in EGFR-mutant NSCLCs treated with EGFR kinase inhibitors.Semantic proximity Read ↗

Differential Responses to Targeted Therapies in Non-Small Cell Lung Cancer: A Comparative Analysis of Outcomes in Patients with Single EGFR Mutation and Concurrent Gene AlterationsSemantic proximity Read ↗

Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer.Semantic proximity Read ↗

An open label phase II study evaluating first-line EGFR tyrosine kinase inhibitor erlotinib in non-small cell lung cancer patients with tumors showing high EGFR gene copy number.Semantic proximity Read ↗

High EGFR copy number predicts benefits from tyrosine kinase inhibitor treatment for non-small cell lung cancer patients with wild-type EGFR.Semantic proximity Read ↗

Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.Semantic proximity Read ↗

[Clinical and molecular predictors of response to EGFR tyrosine kinase inhibitors in non-small cell lung cancer].Semantic proximity Read ↗

Concomitant Genetic Alterations are Associated with Worse Clinical Outcome in EGFR Mutant NSCLC Patients Treated with Tyrosine Kinase InhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.